Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Authors
Keywords
-
Journal
DRUGS
Volume 79, Issue 14, Pages 1591-1598
Publisher
Springer Science and Business Media LLC
Online
2019-09-06
DOI
10.1007/s40265-019-01194-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.
- (2019) Felix Y Feng et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastasis-free survival as a predictor of overall survival in non-metastatic castration-resistant prostate cancer.
- (2019) Richard Gagnon et al. JOURNAL OF CLINICAL ONCOLOGY
- Apalutamide (APA) or enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (CRPC): A systematic review and network meta-analysis of randomized clinical trials (RCTs).
- (2019) Irbaz Bin Riaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).
- (2019) Eric Jay Small et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction
- (2019) John Esther et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).
- (2019) YaoYao Guan Pollock et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM).
- (2019) Eric Jay Small et al. JOURNAL OF CLINICAL ONCOLOGY
- MP34-20 METASTASIS-FREE SURVIVAL (MFS) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH PROSTATE-SPECIFIC ANTIGEN (PSA) DECLINE TO < 0.2 NG/ML FOLLOWING APALUTAMIDE (APA) TREATMENT: POST HOC RESULTS FROM THE PHASE 3 SPARTAN STUDY
- (2019) Julie N. Graff* et al. JOURNAL OF UROLOGY
- MP34-19 EFFICACY AND SAFETY OF APALUTAMIDE (APA) IN NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) PATIENTS (PTS) WITH OR WITHOUT PRIOR RADICAL PROSTATECTOMY (RP) AND/OR EXTERNAL RADIOTHERAPY (XRT): POST HOC ANALYSIS OF SPARTAN
- (2019) Boris A. Hadaschik* et al. JOURNAL OF UROLOGY
- PD11-03 RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIPHER GENOMIC CLASSIFIER (GC) SCORE
- (2019) Fred Saad* et al. JOURNAL OF UROLOGY
- MP34-18 CLINICAL BENEFITS AND RISKS OF ENZALUTAMIDE AND APALUTAMIDE: NUMBER NEEDED TO TREAT AND NUMBER NEEDED TO HARM ANALYSIS FOR PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- (2019) Neil M. Schultz et al. JOURNAL OF UROLOGY
- Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines
- (2018) Michael I. Koukourakis et al. ANTI-CANCER DRUGS
- An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer
- (2018) Bodine P. S. I. Belderbos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Second-generation antiandrogens in nonmetastatic CRPC
- (2018) Robert Chandler et al. Nature Reviews Urology
- Metastasis-free Survival — A New End Point in Prostate Cancer Trials
- (2018) Julia A. Beaver et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract 2605: Androgen receptor (AR) anomalies and efficacy of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 SPARTAN study
- (2018) Matthew R. Smith et al. CANCER RESEARCH
- Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC).
- (2018) Matthew Raymond Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial.
- (2018) Eric Jay Small et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
- (2018) Fred Saad et al. LANCET ONCOLOGY
- 213OEfficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation
- (2018) P Mainwaring et al. ANNALS OF ONCOLOGY
- PCN37 - MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF APALUTAMIDE AND ENZALUTAMIDE IN THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- (2018) S. Chowdhury et al. VALUE IN HEALTH
- PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCER
- (2018) Z. Zhou et al. VALUE IN HEALTH
- Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
- (2016) Matthew R. Smith et al. EUROPEAN UROLOGY
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started